<p>Theravance Biopharma, Inc.（NASDAQ:TBPH - 獲取免費報告）的股票在覆蓋該股票的八家研究公司中獲得了 “適度買入” 的平均評級，MarketBeat Ratings 報告稱。四位分析師給予該股票持有評級，兩位給予買入評級，兩位給予強烈買入評級。在過去一年中，覆蓋該股票的分析師的平均 12 個月目標價為 21.8333 美元。</p>
<p>獲取 <strong>Theravance Biopharma</strong> 的提醒：</p>
<p>TBPH 已成為幾份分析師報告的主題。Zacks Research 在 3 月 19 日的研究報告中將 Theravance Biopharma 的股票評級從 “持有” 上調至 “強烈買入”。B. Riley Financial 在 4 月 7 日的研究報告中將 Theravance Biopharma 的股票目標價從 14.00 美元上調至 17.00 美元，並給予該股票 “中性” 評級。TD Cowen 在 3 月 23 日的研究報告中將 Theravance Biopharma 的股票目標價從 13.00 美元上調至 15.00 美元，並給予該股票 “持有” 評級。Weiss Ratings 在 4 月 10 日的研究報告中將 Theravance Biopharma 的股票評級從 “買入（b-）” 下調至 “持有（c+）”。最後，Oppenheimer 在 3 月 5 日的報告中將 Theravance Biopharma 的股票評級從 “跑贏大盤” 下調至 “市場表現”。</p>
<p><strong>查看我們關於 TBPH 的最新報告</strong></p>
<h2>Theravance Biopharma 股價上漲 0.9%</h2>
<p>NASDAQ TBPH 週五開盤價為 16.46 美元。該公司的 50 日移動平均價格為 16.14 美元，200 日移動平均價格為 17.20 美元。Theravance Biopharma 的一年低點為 8.33 美元，一年高點為 21.03 美元。該公司的市值為 8.4753 億美元，市盈率為 8.11，貝塔值為 0.17。</p>
<h2>Theravance Biopharma 的內部活動</h2>
<p>在其他 Theravance Biopharma 的新聞中，SVP Rhonda Farnum 在 3 月 16 日的交易中出售了 31,067 股公司的股票。這些股票以平均價格 13.96 美元出售，總價值為 433,695.32 美元。交易後，這位高級副總裁直接持有 232,699 股公司股票，價值為 3,248,478.04 美元。此次交易使其持股減少了 11.78%。該交易已在提交給證券交易委員會的文件中披露，文件可在此鏈接查看。目前，6.90% 的股票由公司內部人士持有。</p>
<h2>對 Theravance Biopharma 的對沖基金看法</h2>
<p>幾家機構投資者和對沖基金最近修改了對 TBPH 的持股。AQR Capital Management LLC 在第一季度以約 101,000 美元的價格收購了 Theravance Biopharma 的新頭寸。Jane Street Group LLC 在第一季度將其在 Theravance Biopharma 的股份增加了 169.2%。Jane Street Group LLC 現在擁有 140,884 股該生物製藥公司的股票，價值為 1,258,000 美元，此前在上個季度又收購了 88,540 股。Creative Planning 在第二季度以約 139,000 美元的價格收購了 Theravance Biopharma 的新股份。American Century Companies Inc. 在第二季度將其在 Theravance Biopharma 的股份增加了 6.8%。American Century Companies Inc. 現在擁有 91,501 股該生物製藥公司的股票，價值為 1,009,000 美元，此前在上個季度又購買了 5,794 股。最後，Invesco Ltd. 在第二季度將其在 Theravance Biopharma 的股份增加了 12.4%。Invesco Ltd. 現在擁有 25,324 股該生物製藥公司的股票，價值為 279,000 美元，此前在上個季度又購買了 2,789 股。目前，99.10% 的股票由機構投資者和對沖基金持有。</p>
<h2>Theravance Biopharma 公司簡介</h2>
<p>（獲取免費報告）</p>
<p>Theravance Biopharma 是一家生物製藥公司，專注於創新藥物的發現、開發和商業化，主要涉及呼吸疾病、炎症和免疫學以及罕見疾病領域。該公司開發的小分子療法旨在通過靶向特定的分子通路來滿足未滿足的醫療需求。其主要市場產品 YUPELRI®（revefenacin）吸入溶液是美國批准的首個也是唯一一個每日一次的長效抗膽鹼藥（LAMA）。</p>
<h2>瞭解更多</h2>
<ul>
<li>我們更看好的五隻股票，勝過 Theravance Biopharma</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VEJQSA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VEJQSA"/></p>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 Theravance Biopharma 嗎？</h2>
<p>在你考慮 Theravance Biopharma 之前，你會想聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦現在購買，以便在更廣泛的市場注意到之前……而 Theravance Biopharma 並不在名單上。</p>
<p>雖然 Theravance Biopharma 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

Theravance生物制藥

<p>Theravance Biopharma, Inc.（納斯達克代碼：TBPH）獲得了八家研究公司的 “適度買入” 共識評級。分析師的評級包括四個持有、兩個買入和兩個強力買入，平均 12 個月目標價為 21.83 美元。最近的報告顯示評級各異，Zacks 將評級上調至強力買入，B. Riley Financial 將目標價提高至 17.00 美元。該股票目前交易價格為 16.46 美元，市值為 8.4753 億美元。機構投資者持有 99.10% 的股份，顯示出對公司的強烈興趣</p>

<p>Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH - Get Free Report) have been given an average rating of &#34;Moderate Buy&#34; by the eight research firms that are covering the stock, MarketBeat Ratings reports. Four analysts have rated the stock with a hold rating, two have given a buy rating and two have issued a strong buy rating on the company. The average 12-month price target among analysts that have covered the stock in the last year is $21.8333.</p>
<div class="lb-trans"><p>Theravance Biopharma, Inc.（NASDAQ:TBPH - 獲取免費報告）的股票在覆蓋該股票的八家研究公司中獲得了 “適度買入” 的平均評級，MarketBeat Ratings 報告稱。四位分析師給予該股票持有評級，兩位給予買入評級，兩位給予強烈買入評級。在過去一年中，覆蓋該股票的分析師的平均 12 個月目標價為 21.8333 美元。</p>
</div><p>Get <strong>Theravance Biopharma</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Theravance Biopharma</strong> 的提醒：</p>
</div><p>TBPH has been the topic of several analyst reports. Zacks Research raised shares of Theravance Biopharma from a &#34;hold&#34; rating to a &#34;strong-buy&#34; rating in a research report on Thursday, March 19th. B. Riley Financial upped their price target on shares of Theravance Biopharma from $14.00 to $17.00 and gave the stock a &#34;neutral&#34; rating in a research report on Tuesday, April 7th. TD Cowen upped their price target on shares of Theravance Biopharma from $13.00 to $15.00 and gave the stock a &#34;hold&#34; rating in a research report on Monday, March 23rd. Weiss Ratings lowered shares of Theravance Biopharma from a &#34;buy (b-)&#34; rating to a &#34;hold (c+)&#34; rating in a research report on Friday, April 10th. Finally, Oppenheimer downgraded shares of Theravance Biopharma from an &#34;outperform&#34; rating to a &#34;market perform&#34; rating in a report on Thursday, March 5th.</p>
<div class="lb-trans"><p>TBPH 已成為幾份分析師報告的主題。Zacks Research 在 3 月 19 日的研究報告中將 Theravance Biopharma 的股票評級從 “持有” 上調至 “強烈買入”。B. Riley Financial 在 4 月 7 日的研究報告中將 Theravance Biopharma 的股票目標價從 14.00 美元上調至 17.00 美元，並給予該股票 “中性” 評級。TD Cowen 在 3 月 23 日的研究報告中將 Theravance Biopharma 的股票目標價從 13.00 美元上調至 15.00 美元，並給予該股票 “持有” 評級。Weiss Ratings 在 4 月 10 日的研究報告中將 Theravance Biopharma 的股票評級從 “買入（b-）” 下調至 “持有（c+）”。最後，Oppenheimer 在 3 月 5 日的報告中將 Theravance Biopharma 的股票評級從 “跑贏大盤” 下調至 “市場表現”。</p>
</div><p><strong>Check Out Our Latest Report on TBPH</strong></p>
<div class="lb-trans"><p><strong>查看我們關於 TBPH 的最新報告</strong></p>
</div><h2>Theravance Biopharma Trading Up 0.9%</h2>
<div class="lb-trans"><h2>Theravance Biopharma 股價上漲 0.9%</h2>
</div><p>NASDAQ TBPH opened at $16.46 on Friday. The firm's fifty day moving average price is $16.14 and its two-hundred day moving average price is $17.20. Theravance Biopharma has a 1 year low of $8.33 and a 1 year high of $21.03. The firm has a market capitalization of $847.53 million, a P/E ratio of 8.11 and a beta of 0.17.</p>
<div class="lb-trans"><p>NASDAQ TBPH 週五開盤價為 16.46 美元。該公司的 50 日移動平均價格為 16.14 美元，200 日移動平均價格為 17.20 美元。Theravance Biopharma 的一年低點為 8.33 美元，一年高點為 21.03 美元。該公司的市值為 8.4753 億美元，市盈率為 8.11，貝塔值為 0.17。</p>
</div><h2>Insider Activity at Theravance Biopharma</h2>
<div class="lb-trans"><h2>Theravance Biopharma 的內部活動</h2>
</div><p>In other Theravance Biopharma news, SVP Rhonda Farnum sold 31,067 shares of the company's stock in a transaction on Monday, March 16th. The shares were sold at an average price of $13.96, for a total value of $433,695.32. Following the transaction, the senior vice president directly owned 232,699 shares in the company, valued at $3,248,478.04. The trade was a 11.78% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities &amp; Exchange Commission, which is available at this hyperlink. 6.90% of the stock is currently owned by corporate insiders.</p>
<div class="lb-trans"><p>在其他 Theravance Biopharma 的新聞中，SVP Rhonda Farnum 在 3 月 16 日的交易中出售了 31,067 股公司的股票。這些股票以平均價格 13.96 美元出售，總價值為 433,695.32 美元。交易後，這位高級副總裁直接持有 232,699 股公司股票，價值為 3,248,478.04 美元。此次交易使其持股減少了 11.78%。該交易已在提交給證券交易委員會的文件中披露，文件可在此鏈接查看。目前，6.90% 的股票由公司內部人士持有。</p>
</div><h2>Hedge Funds Weigh In On Theravance Biopharma</h2>
<div class="lb-trans"><h2>對 Theravance Biopharma 的對沖基金看法</h2>
</div><p>Several institutional investors and hedge funds have recently modified their holdings of TBPH. AQR Capital Management LLC acquired a new position in shares of Theravance Biopharma in the first quarter valued at about $101,000. Jane Street Group LLC grew its stake in shares of Theravance Biopharma by 169.2% in the first quarter. Jane Street Group LLC now owns 140,884 shares of the biopharmaceutical company's stock valued at $1,258,000 after acquiring an additional 88,540 shares in the last quarter. Creative Planning acquired a new stake in shares of Theravance Biopharma in the second quarter valued at approximately $139,000. American Century Companies Inc. raised its position in shares of Theravance Biopharma by 6.8% in the second quarter. American Century Companies Inc. now owns 91,501 shares of the biopharmaceutical company's stock valued at $1,009,000 after buying an additional 5,794 shares in the last quarter. Finally, Invesco Ltd. raised its position in shares of Theravance Biopharma by 12.4% in the second quarter. Invesco Ltd. now owns 25,324 shares of the biopharmaceutical company's stock valued at $279,000 after buying an additional 2,789 shares in the last quarter. 99.10% of the stock is currently owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>幾家機構投資者和對沖基金最近修改了對 TBPH 的持股。AQR Capital Management LLC 在第一季度以約 101,000 美元的價格收購了 Theravance Biopharma 的新頭寸。Jane Street Group LLC 在第一季度將其在 Theravance Biopharma 的股份增加了 169.2%。Jane Street Group LLC 現在擁有 140,884 股該生物製藥公司的股票，價值為 1,258,000 美元，此前在上個季度又收購了 88,540 股。Creative Planning 在第二季度以約 139,000 美元的價格收購了 Theravance Biopharma 的新股份。American Century Companies Inc. 在第二季度將其在 Theravance Biopharma 的股份增加了 6.8%。American Century Companies Inc. 現在擁有 91,501 股該生物製藥公司的股票，價值為 1,009,000 美元，此前在上個季度又購買了 5,794 股。最後，Invesco Ltd. 在第二季度將其在 Theravance Biopharma 的股份增加了 12.4%。Invesco Ltd. 現在擁有 25,324 股該生物製藥公司的股票，價值為 279,000 美元，此前在上個季度又購買了 2,789 股。目前，99.10% 的股票由機構投資者和對沖基金持有。</p>
</div><h2>Theravance Biopharma Company Profile</h2>
<div class="lb-trans"><h2>Theravance Biopharma 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.</p>
<div class="lb-trans"><p>Theravance Biopharma 是一家生物製藥公司，專注於創新藥物的發現、開發和商業化，主要涉及呼吸疾病、炎症和免疫學以及罕見疾病領域。該公司開發的小分子療法旨在通過靶向特定的分子通路來滿足未滿足的醫療需求。其主要市場產品 YUPELRI®（revefenacin）吸入溶液是美國批准的首個也是唯一一個每日一次的長效抗膽鹼藥（LAMA）。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>瞭解更多</h2>
</div><ul>
<li>Five stocks we like better than Theravance Biopharma</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票，勝過 Theravance Biopharma</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VEJQSA" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=TBPH"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Theravance Biopharma Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Theravance Biopharma 嗎？</h2>
</div><p>Before you consider Theravance Biopharma, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮 Theravance Biopharma 之前，你會想聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Theravance Biopharma wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦現在購買，以便在更廣泛的市場注意到之前……而 Theravance Biopharma 並不在名單上。</p>
</div><p>While Theravance Biopharma currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Theravance Biopharma 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Theravance Biopharma, Inc. (NASDAQ:TBPH) Given Consensus Rating of "Moderate Buy" by Brokerages

Market Beat

奧本海默控股

景順投資管理

B Riley Financial Pref Share RILYL 7.375 Perp 09/04/25 B

B Riley Financial Pref Share RILYG 7.25 12/21/27

B Riley Financial Pref Share RILYN 6.5 09/30/2026

B Riley Financial Pref Share RILYK 5.5 03/31/26

B. Riley Financial-存託優先股A

B Riley Financial Pref Share RILYZ 5.25 08/31/28

B Riley Financial Pref Share RILYT 6.0 01/31/28

Theravance 生物製藥公司（NASDAQ:TBPH）被券商一致評為 “適度買入”